Skip to main content

Table 3 Increase in the relative frequency (%) of different outcomes and the number needed to treat (NNT) with respective 95% CIs calculated using a normal approximation compared to the placebo. - Data were not reported in the studies. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

Outcome ASAS20 ASAS40 ASAS PR
Follow-up time (weeks)
12 to 16 24 12 to 16 24 12 to 16 24
Drug % NNT (95% CI) % NNT (95% CI) % NNT (95% CI) % NNT (95% CI) % NNT (95% CI) % NNT (95% CI)
Infliximab [111] 42 2.4 (1.9–3.2) 35 2.9 (2.2–4.0) 21 4.7 (3.7–6.7)
Etanercept [113, 119, 120, 123] 27 3.7 (2.9–5.1) 34 2.9 (2.2–4.3) 18 5.5 (3.6–11.7) 13 7.5 (3.7-∞) 13 7.6 (4.9–16.9)
Adalimumab [126, 130, 131] 27 3.7 (2.8–5.2) 26 3.8 (3.0–5.2) 26 3.8 (2.8–5.8) 16 6.4 (4.8–9.5) 17 6.1 (4.2–10.7)
Golimumab [133, 137, 138] 37 2.7 (2.3–3.4) 40 2.5 (2.1–3.2) 28 3.6 (2.5–6.0) 7.5 (4.8–16.3)
Certolizumab pegol [139] 22 4.5 (3.0–9.1) 28 3.6 (2.6–5.5) 20 5.0 (3.7–7.5)
Secukinumab [142] 36 2.8 (2.2–3.8) 30 3.3 (2.5–4.6) 12 8.1 (5.4–16.0)